QT Interval Monitoring and Drugs Management During COVID-19 Pandemic. 2021

Alessio Gasperetti, and Marco Schiavone, and Claudio Tondo, and Gianfranco Mitacchione, and Maurizio Viecca, and Massimo Galli, and Piercarlo Sarzi-Puttini, and Giovanni B Forleo
Department of Cardiology, ASST-Fatebenefratelli Sacco, Luigi Sacco University Hospital, Milan, Italy.

While facing potentially high morbidity from COVID-19 without known effective therapies, the off-label use of several non-specific drugs has been advocated, including re-purposed anti- viral (e.g., remdesivir or the lopinavir/ritonavir combination), biologic agents (e.g., tocilizumab), and antimalarial drugs such as chloroquine and hydroxychloroquine, in association with or without azithromycin. Data regarding the effectiveness of these drugs in treating COVID-19 has been shown in some trials and clinical settings, but further randomised controlled trials are still being carried out. One of the main concerns regarding their widespread use, however, is their possible effects on the QT interval and arrhythmogenic potential. Some of these drugs have been associated with QT prolongation and Torsades de Point, a potentially lethal ventricular arrhythmia. The review aims to highlight the magnitude of this problem, to quickly refresh clinically impacting cornerstones of QT interval and TdP pathophysiology, to summarize the available evidence regarding the QT and arrhythmia impact of drugs used in different clinical settings in COVID-19 patients, and to help the physicians dealing with the knowledge needed in the everyday clinical duties in case of doubts regarding QT-induced arrhythmias in this time of emergency.

UI MeSH Term Description Entries
D004364 Pharmaceutical Preparations Drugs intended for human or veterinary use, presented in their finished dosage form. Included here are materials used in the preparation and/or formulation of the finished dosage form. Drug,Drugs,Pharmaceutical,Pharmaceutical Preparation,Pharmaceutical Product,Pharmaceutic Preparations,Pharmaceutical Products,Pharmaceuticals,Preparations, Pharmaceutical,Preparation, Pharmaceutical,Preparations, Pharmaceutic,Product, Pharmaceutical,Products, Pharmaceutical
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006886 Hydroxychloroquine A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970) Hydroxychlorochin,Oxychlorochin,Oxychloroquine,Hydroxychloroquine Sulfate,Hydroxychloroquine Sulfate (1:1) Salt,Plaquenil
D000086382 COVID-19 A viral disorder generally characterized by high FEVER; COUGH; DYSPNEA; CHILLS; PERSISTENT TREMOR; MUSCLE PAIN; HEADACHE; SORE THROAT; a new loss of taste and/or smell (see AGEUSIA and ANOSMIA) and other symptoms of a VIRAL PNEUMONIA. In severe cases, a myriad of coagulopathy associated symptoms often correlating with COVID-19 severity is seen (e.g., BLOOD COAGULATION; THROMBOSIS; ACUTE RESPIRATORY DISTRESS SYNDROME; SEIZURES; HEART ATTACK; STROKE; multiple CEREBRAL INFARCTIONS; KIDNEY FAILURE; catastrophic ANTIPHOSPHOLIPID ANTIBODY SYNDROME and/or DISSEMINATED INTRAVASCULAR COAGULATION). In younger patients, rare inflammatory syndromes are sometimes associated with COVID-19 (e.g., atypical KAWASAKI SYNDROME; TOXIC SHOCK SYNDROME; pediatric multisystem inflammatory disease; and CYTOKINE STORM SYNDROME). A coronavirus, SARS-CoV-2, in the genus BETACORONAVIRUS is the causative agent. 2019 Novel Coronavirus Disease,2019 Novel Coronavirus Infection,2019-nCoV Disease,2019-nCoV Infection,COVID-19 Pandemic,COVID-19 Pandemics,COVID-19 Virus Disease,COVID-19 Virus Infection,Coronavirus Disease 2019,Coronavirus Disease-19,SARS Coronavirus 2 Infection,SARS-CoV-2 Infection,Severe Acute Respiratory Syndrome Coronavirus 2 Infection,COVID19,2019 nCoV Disease,2019 nCoV Infection,2019-nCoV Diseases,2019-nCoV Infections,COVID 19,COVID 19 Pandemic,COVID 19 Virus Disease,COVID 19 Virus Infection,COVID-19 Virus Diseases,COVID-19 Virus Infections,Coronavirus Disease 19,Disease 2019, Coronavirus,Disease, 2019-nCoV,Disease, COVID-19 Virus,Infection, 2019-nCoV,Infection, COVID-19 Virus,Infection, SARS-CoV-2,Pandemic, COVID-19,SARS CoV 2 Infection,SARS-CoV-2 Infections,Virus Disease, COVID-19,Virus Infection, COVID-19
D000086402 SARS-CoV-2 A species of BETACORONAVIRUS causing atypical respiratory disease (COVID-19) in humans. The organism was first identified in 2019 in Wuhan, China. The natural host is the Chinese intermediate horseshoe bat, RHINOLOPHUS affinis. 2019 Novel Coronavirus,COVID-19 Virus,COVID19 Virus,Coronavirus Disease 2019 Virus,SARS Coronavirus 2,SARS-CoV-2 Virus,Severe Acute Respiratory Syndrome Coronavirus 2,Wuhan Coronavirus,Wuhan Seafood Market Pneumonia Virus,2019-nCoV,2019 Novel Coronaviruses,COVID 19 Virus,COVID-19 Viruses,COVID19 Viruses,Coronavirus 2, SARS,Coronavirus, 2019 Novel,Coronavirus, Wuhan,Novel Coronavirus, 2019,SARS CoV 2 Virus,SARS-CoV-2 Viruses,Virus, COVID-19,Virus, COVID19,Virus, SARS-CoV-2,Viruses, COVID19
D058873 Pandemics Epidemics of infectious disease that have spread to many countries, often more than one continent, and usually affecting a large number of people. Pandemic

Related Publications

Alessio Gasperetti, and Marco Schiavone, and Claudio Tondo, and Gianfranco Mitacchione, and Maurizio Viecca, and Massimo Galli, and Piercarlo Sarzi-Puttini, and Giovanni B Forleo
July 2020, Circulation,
Alessio Gasperetti, and Marco Schiavone, and Claudio Tondo, and Gianfranco Mitacchione, and Maurizio Viecca, and Massimo Galli, and Piercarlo Sarzi-Puttini, and Giovanni B Forleo
January 2022, International journal of vascular medicine,
Alessio Gasperetti, and Marco Schiavone, and Claudio Tondo, and Gianfranco Mitacchione, and Maurizio Viecca, and Massimo Galli, and Piercarlo Sarzi-Puttini, and Giovanni B Forleo
February 2021, International journal of cardiology. Heart & vasculature,
Alessio Gasperetti, and Marco Schiavone, and Claudio Tondo, and Gianfranco Mitacchione, and Maurizio Viecca, and Massimo Galli, and Piercarlo Sarzi-Puttini, and Giovanni B Forleo
October 2020, International journal of cardiology. Heart & vasculature,
Alessio Gasperetti, and Marco Schiavone, and Claudio Tondo, and Gianfranco Mitacchione, and Maurizio Viecca, and Massimo Galli, and Piercarlo Sarzi-Puttini, and Giovanni B Forleo
July 2023, Scientific reports,
Alessio Gasperetti, and Marco Schiavone, and Claudio Tondo, and Gianfranco Mitacchione, and Maurizio Viecca, and Massimo Galli, and Piercarlo Sarzi-Puttini, and Giovanni B Forleo
August 2020, Kardiologiia,
Alessio Gasperetti, and Marco Schiavone, and Claudio Tondo, and Gianfranco Mitacchione, and Maurizio Viecca, and Massimo Galli, and Piercarlo Sarzi-Puttini, and Giovanni B Forleo
March 2021, JAMA cardiology,
Alessio Gasperetti, and Marco Schiavone, and Claudio Tondo, and Gianfranco Mitacchione, and Maurizio Viecca, and Massimo Galli, and Piercarlo Sarzi-Puttini, and Giovanni B Forleo
March 2021, JAMA cardiology,
Alessio Gasperetti, and Marco Schiavone, and Claudio Tondo, and Gianfranco Mitacchione, and Maurizio Viecca, and Massimo Galli, and Piercarlo Sarzi-Puttini, and Giovanni B Forleo
June 2021, Global heart,
Alessio Gasperetti, and Marco Schiavone, and Claudio Tondo, and Gianfranco Mitacchione, and Maurizio Viecca, and Massimo Galli, and Piercarlo Sarzi-Puttini, and Giovanni B Forleo
March 2021, JAMA cardiology,
Copied contents to your clipboard!